NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free AQST Stock Alerts $3.11 -0.17 (-5.18%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.3250-Day Range$3.09▼$6.0952-Week Range$1.25▼$6.23Volume837,219 shsAverage Volume2.19 million shsMarket Capitalization$283.13 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aquestive Therapeutics alerts: Email Address Aquestive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside157.2% Upside$8.00 Price TargetShort InterestBearish5.79% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 6 Articles This WeekInsider TradingSelling Shares$429,750 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.42) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector412th out of 920 stocksPharmaceutical Preparations Industry186th out of 426 stocks 4.6 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aquestive Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.79% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 31.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 2.4 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.Search Interest30 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $429,750.00 in company stock.Percentage Held by InsidersOnly 8.39% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.42) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Aquestive Therapeutics Stock (NASDAQ:AQST)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesMay 13, 2024 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.00 Consensus PT from BrokeragesMay 12, 2024 | americanbankingnews.comAquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from HC WainwrightMay 12, 2024 | americanbankingnews.comSVB Leerink Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Solid Finances and Promising Anaphylm™ ProspectsMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call TranscriptMay 9, 2024 | globenewswire.comAquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 9, 2024 | finance.yahoo.comAquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)May 8, 2024 | wsj.comAquestive Therapeutics Inc.May 7, 2024 | investorplace.comAQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | msn.comAquestive Therapeutics GAAP EPS of -$0.17, revenue of $12.05MMay 7, 2024 | globenewswire.comAquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 30, 2024 | markets.businessinsider.comAquestive Therapeutics Earns Buy Rating on Libervant’s Pediatric Approval and Anaphylm’s Market PotentialApril 29, 2024 | msn.comAquestive stock falls amid Libervant approval, Anaphylm updateApril 29, 2024 | finance.yahoo.comAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual FilmApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth ProspectsApril 25, 2024 | finance.yahoo.comAquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ETApril 17, 2024 | investorplace.comComing FDA Approvals Could Send These 3 Drug Stocks SoaringApril 12, 2024 | globenewswire.comAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyApril 11, 2024 | msn.comPiper starts Aquestive at overweight, cites allergy reaction treatmentApril 11, 2024 | msn.comAquestive Therapeutics a new overweight at Piper on oral film productsMarch 25, 2024 | globenewswire.comAquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockMarch 20, 2024 | msn.comAquestive Therapeutics slumps 13%, prices $75M offeringMarch 20, 2024 | investorplace.comWhy Is Aquestive Therapeutics (AQST) Stock Down 14% Today?See More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today5/18/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+157.2%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-55.85% Pretax Margin-55.38% Return on EquityN/A Return on Assets-37.93% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio5.85 Sales & Book Value Annual Sales$50.58 million Price / Sales5.60 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-7.78Miscellaneous Outstanding Shares91,040,000Free Float83,401,000Market Cap$283.13 million OptionableOptionable Beta2.95 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Daniel Barber (Age 48)CEO, President & Director Comp: $925.35kMr. Alexander Mark Schobel (Age 65)Chief Innovation & Technology Officer Comp: $672.69kMs. Lori J. Braender BSBA (Age 68)Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $678.76kMr. A. Ernest Toth Jr. (Age 65)Chief Financial Officer Comp: $679.9kMs. Cassie Jung (Age 45)Senior Vice President of Operations Mr. Peter E. Boyd (Age 58)Senior Vice President of IT, HR & Communications Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Stephen Wargacki (Age 46)Senior VP of Research & Development Dr. Carl N. Kraus M.D. (Age 54)Chief Medical Officer Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant SecretaryMore ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANICorMedixNASDAQ:CRMDVentyx BiosciencesNASDAQ:VTYXNature's Sunshine ProductsNASDAQ:NATRNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInsiders & InstitutionsLazard Asset Management LLCBought 15,601 shares on 5/15/2024Ownership: 0.032%Vanguard Group Inc.Bought 1,353,518 shares on 5/10/2024Ownership: 3.562%Acadian Asset Management LLCSold 16,917 shares on 5/10/2024Ownership: 0.586%SG Americas Securities LLCBought 12,625 shares on 5/7/2024Ownership: 0.014%Essex Investment Management Co. LLCSold 233,218 shares on 5/3/2024Ownership: 0.673%View All Insider TransactionsView All Institutional Transactions AQST Stock Analysis - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12 month price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 157.2% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2024? Aquestive Therapeutics' stock was trading at $2.02 at the start of the year. Since then, AQST stock has increased by 54.0% and is now trading at $3.11. View the best growth stocks for 2024 here. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. The firm had revenue of $12.05 million for the quarter, compared to the consensus estimate of $12.22 million. During the same quarter in the prior year, the firm earned $0.11 EPS. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $48.0 million-$51.0 million, compared to the consensus revenue estimate of $50.2 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.56%), Essex Investment Management Co. LLC (0.67%), Acadian Asset Management LLC (0.59%), Janney Montgomery Scott LLC (0.38%), PFG Investments LLC (0.07%) and Lazard Asset Management LLC (0.03%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AQST) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
